DOPAR
LOE ApproachingNDAORALTABLET
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DOPAR is an oral tablet small molecule approved in 1970 by Takeda with an unknown mechanism of action and indication profile. The drug is a legacy NDA product currently approaching loss of exclusivity. Patient population and therapeutic mechanism cannot be determined from available data.
LOE Approaching
As a legacy product approaching LOE with minimal competitive pressure data (30 score), the brand team is likely small and focused on portfolio defense rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Efficacy and Safety of Entacapone Combined With Madopar in the Treatment of Early Parkinson's Disease: An Observational, Multicenter, Case-Control Study
Started Jun 2025
216 enrolled
Parkinson Disease (PD)
Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome
Started Feb 2003
58 enrolled
Restless Legs Syndrome
Career Relevance
DOPAR has zero linked job opportunities and is a legacy product with no active expansion pipeline. Roles associated with this product are primarily focused on maintaining market presence and managing the transition to generic competition, offering limited career advancement.
Worked on DOPAR at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.